Výsledky vyhledávání - "Hiromi TABUCHI"

Akademický článek

Impact of body mass index on the efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes mellitus: A subgroup analysis of 3‐month interim results from the Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use study

Autor: Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Ichiro Nakamura, Satoshi Uno

Publikováno v: Journal of Diabetes Investigation, Vol 10, Iss 5, Pp 1262-1271 (2019)

Abstract Aims/Introduction Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use is an ongoing postmarketing study of ipragliflozin for long‐term use in Japanese patients with type 2 diabetes mell

Externí odkaz: https://doaj.org/article/cb20c8c11187498b856d7887507a33ce

Zobrazit plný text záznamu

Plný text ve formátu HTML

Safety and effectiveness of mirabegron in male patients with overactive bladder with or without benign prostatic hyperplasia: A Japanese post‐marketing study

Autor: Hiromi Tabuchi, Satoru Takahashi, Daisuke Kato, Satoshi Uno

Publikováno v: Lower Urinary Tract Symptoms

Objectives The aim of this post hoc analysis from the Japanese mirabegron surveillance program was to investigate the safety and effectiveness of mirabegron in male patients with overactive bladder (OAB) symptoms with/without concomitant benign prost

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eee124fe7b7b757860d92fbe73a66af0
http://europepmc.org/articles/PMC7818393

Zobrazit plný text záznamu

Autor: Ichiro Nakamura, Satoshi Uno, Kazuyuki Tobe, Hiromi Tabuchi, Hiroshi Maegawa

Publikováno v: Journal of Diabetes Investigation
Journal of Diabetes Investigation, Vol 10, Iss 5, Pp 1262-1271 (2019)

Aims/Introduction Specified Drug Use Results Survey of Ipragliflozin Treatment in Type 2 Diabetic Patients: Long‐term Use is an ongoing postmarketing study of ipragliflozin for long‐term use in Japanese patients with type 2 diabetes mellitus. A s

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0c3dcf7dbc152512af7cf4e0ccff213f
https://doi.org/10.1111/jdi.13021

Zobrazit plný text záznamu

Plný text ve formátu HTML

Safety and efficacy of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice: interim results of the STELLA-LONG TERM post-marketing surveillance study

Autor: Ichiro Nakamura, Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Satoshi Uno

Publikováno v: Expert Opinion on Pharmacotherapy. 19:189-201

Data regarding the efficacy and safety of sodium-glucose cotransporter 2 inhibitors in the real-world setting in Japan are limited. The STELLA-LONG TERM study is an ongoing 3-year post-marketing surveillance study of ipragliflozin in type 2 diabetes

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4811db360ea9a27c484ecf0ab6212fcb
https://doi.org/10.1080/14656566.2017.1408792

Zobrazit plný text záznamu

Safety and effectiveness of mirabegron in patients with overactive bladder aged ≥75 years: Analysis of a Japanese post-marketing study

Autor: Yumiko Nozawa, Daisuke Kato, Kentarou Kuroishi, Hiromi Tabuchi, Masaki Yoshida

Publikováno v: LUTS: Lower Urinary Tract Symptoms. 11:30-38

Objectives A 12-week post-marketing study was conducted to provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with mirabegron. This post-hoc analysis focused on safety and effectiveness of mirabegron in pa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba2c63525c6ea717d15844258aad707c
https://doi.org/10.1111/luts.12190

Zobrazit plný text záznamu

Safety, efficacy, and persistence of long-term mirabegron treatment for overactive bladder in the daily clinical setting:Interim (1-year) report from a Japanese post-marketing surveillance study

Autor: Hiromi Tabuchi, Daisuke Kato, Satoshi Uno

Publikováno v: LUTS: Lower Urinary Tract Symptoms. 11:14-23

OBJECTIVES To report interim 1-year results from a 3-year surveillance study evaluating safety, efficacy, and persistence of long-term mirabegron for overactive bladder (OAB). METHODS Patients starting treatment with mirabegron for urinary urgency, d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ac7ed3d32e8574e04ff78a6131157757
https://doi.org/10.1111/luts.12188

Zobrazit plný text záznamu

Safety and Effectiveness of Mirabegron in Patients with Overactive Bladder in a Real-World Clinical Setting: A Japanese Post-Marketing Study

Autor: Kentarou Kuroishi, Yumiko Nozawa, Hiromi Tabuchi, Daisuke Kato

Publikováno v: LUTS: Lower Urinary Tract Symptoms. 10:122-130

Objectives To provide real-world data on Japanese patients with overactive bladder (OAB) initiating treatment with the β3-adrenoceptor agonist, mirabegron. This study examined prescribing patterns, adverse drug reaction (ADR) incidence, and treatmen

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4d47630c11619a9afc4d8b3fb892a201
https://doi.org/10.1111/luts.12148

Zobrazit plný text záznamu

Baseline characteristics and interim (3-month) efficacy and safety data from STELLA-LONG TERM, a long-term post-marketing surveillance study of ipragliflozin in Japanese patients with type 2 diabetes in real-world clinical practice

Autor: Ichiro Nakamura, Hiroshi Maegawa, Kazuyuki Tobe, Hiromi Tabuchi

Publikováno v: Expert Opinion on Pharmacotherapy. 17:1985-1994

To evaluate the efficacy and safety of ipragliflozin in real-world clinical practice in Japanese patients with type 2 diabetes.We conducted interim analyses at 3 months of a 3-year prospective study of patients who were first prescribed ipragliflozin

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c64180835f78b7a42a99ed5f3671fd9b
https://doi.org/10.1080/14656566.2016.1217994

Zobrazit plný text záznamu

Effect of ipragliflozin on liver function in Japanese type 2 diabetes mellitus patients: a subgroup analysis of the STELLA-LONG TERM study (3-month interim results)

Autor: Kazuyuki Tobe, Hiroshi Maegawa, Hiromi Tabuchi, Satoshi Uno, Ichiro Nakamura

Publikováno v: Endocrine journal. 66(1)

This subgroup analysis of STELLA-LONG TERM, an ongoing 3-year post-marketing surveillance study on the long-term efficacy and safety of ipragliflozin, assessed the effect of ipragliflozin on liver function in type 2 diabetes mellitus (T2DM) patients.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8e136e20165857207708b6173c36049e
https://pubmed.ncbi.nlm.nih.gov/30393249

Zobrazit plný text záznamu

Three-year safety, efficacy and persistence data following the daily use of mirabegron for overactive bladder in the clinical setting: A Japanese post-marketing surveillance study

Autor: Daisuke Kato, Hiromi Tabuchi, Satoshi Uno

Publikováno v: Lower Urinary Tract Symptoms

OBJECTIVE The aim of this study was to report the final 3-year results from a surveillance study evaluating the safety, efficacy, and persistence of mirabegron for treating overactive bladder (OAB) symptoms. METHODS Patients who had started mirabegro

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3c64a1ff6d0cfc0d76c220b98cfb5082
https://pubmed.ncbi.nlm.nih.gov/30079630

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání